Comparison of Efficacy of Azithromycin Alone vs Combination of Azithromycin and Probiotics in Management of Mild to Moderate Acne Vulgaris

Phase 4Active Not RecruitingNCT07384793

Hayatabad Medical Complex60 enrolled

Overview

The Goal of this Clinical trial is to compare the efficacy of oral azithromycin alone with combination therapy of oral azithromycin and probiotics to see is there any significant difference in outcome of two treatment modalities in mild to moderate acne vulgaris

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Acne Vulgaris II or III Degree

Interventions

Azithromycin 250 MG Oral CapsuleDRUG

The participants in this arm of study will receive only Oral Azithromycin 250mg on alternate day for 12 weeks to treat their Acne

Azithromycin 250 MG Oral Capsule Along with Oral ProbioticsDRUG

The participants in this arm of study will receive only Oral Azithromycin 250mg on alternate day along with oral probiotics daily for 12 weeks to treat their Acne

Eligibility

Sex: ALLMin age: 15 YearsMax age: 35 Years

Medical Language ↔ Plain English

Inclusion Criteria: Participants with mild to moderate acne on basis of global acne assessment scale score of 2 or 3 and with 20 to 50 total lesion count will be included. \- Exclusion Criteria: History of active localized or generalized infection History of autoimmune disease History of other facial skin diseases/ excessive facial hair or scars History of using isotretinoin or oral contraceptive pills in past 6 months History of already using antibiotics for acne treatment History of facial cosmetic procedures within last 3 months History of allergy to drugs used in study History of using drugs that may interact with azithromycin Currently pregnant or lactating women

Locations (1)

Hayatabad Medical Complex

Peshawar, Pakistan

Outcomes

Primary Outcomes

Reduction of Acne Lesion Count as per Acne Global assessment scale

The patients will be assessed before and after the treatment and their lesions will be counted .The Primary outcome that will be measured is the reduction of the lesion counts according to the Acne global Assessment scale The participants included will be with mild to moderate acne on basis of global acne assessment scale score of 2 or 3. The minimum Lesion count considered will be 20 and the Maximum will be 50. Lower is better Higher is worse.

Time frame: 12 Weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.